Cholinotrophic basal forebrain system alterations in 3xTg-AD transgenic mice

Neurobiology of Disease

Volumn 41, Issue 2, 2011, Pages 338-352

  Perez, Sylvia E ^a   He, Bin ^a   Muhammad, Nadeem ^a   Oh, Kwang Jin ^a   Fahnestock, Margaret ^b   Ikonomovic, Milos D ^c,d   Mufson, Elliott J ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d VA Pittsburgh Healthcare System   (United States)

Author keywords

Aging; Alzheimer's disease; Amyloid; ChAT; Cholinergic; Nerve growth factor; P75 NTR; ProNGF; Transgenic mice; TrkA

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHOLINE ACETYLTRANSFERASE; NERVE GROWTH FACTOR; PROTEIN P75; PROTEIN TYROSINE KINASE A;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAGONAL BAND OF BROCA; ENZYME ACTIVITY; FEMALE; FOREBRAIN; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MOUSE MUTANT; NEURITE; NEUROANATOMY; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; SENILE PLAQUE; SEX DIFFERENCE; STEREOMETRY; TISSUE LEVEL; TRANSGENIC MOUSE; WILD TYPE;

ACETYLCHOLINE; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BASAL NUCLEUS OF MEYNERT; CHOLINERGIC FIBERS; DISEASE MODELS, ANIMAL; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MICE; MICE, TRANSGENIC; PLAQUE, AMYLOID; SEX CHARACTERISTICS;

EID: 78650679481     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.10.002     Document Type: Article

References (91)

1. Amaral D.G., Kurz J. An analysis of the origins of the cholinergic and noncholinergic septal projections to the hippocampal formation of the rat. J. Comp. Neurol. 1985, 240:37-59.
2. Arnold S.E., Hyman B.T., Flory J., Damasio A.R., Van Hoesen G.W. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb. Cortex 1991, 1:103-116.
3. Aucoin J.S., Jiang P., Aznavour N., Tong X.K., Buttini M., Descarries L., Hamel E. Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer's disease. Neuroscience 2005, 132:73-86.
4. Barrett G.L., Bartlett P.F. The p75 nerve growth factor receptor mediates survival or death depending on the stage of sensory neuron development. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:6501-6505.
5. Bell K.F., de Kort G.J., Steggerda S., Shigemoto R., Ribeiro-da-Silva A., Cuello A.C. Structural involvement of the glutamatergic presynaptic boutons in a transgenic mouse model expressing early onset amyloid pathology. Neurosci. Lett. 2003, 353:143-147.
6. Bell K.F., Ducatenzeiler A., Ribeiro-da-Silva A., Duff K., Bennett D.A., Cuello A.C. The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiol. Aging 2005, 27:1644-1657.
7. Boncristiano S., Calhoun M.E., Kelly P.H., Pfeifer M., Bondolfi L., Stalder M., Phinney A.L., Abramowski D., Sturchler-Pierrat C., Enz A., Sommer B., Staufenbiel M., Jucker M. Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J. Neurosci. 2002, 22:3234-3243.
8. Brendza R.P., O'Brien C., Simmons K., McKeel D.W., Bales K.R., Paul S.M., Olney J.W., Sanes J.R., Holtzman D.M. PDAPP; YFP double transgenic mice: a tool to study amyloid-beta associated changes in axonal, dendritic, and synaptic structures. J. Comp. Neurol. 2003, 456:375-383.
9. Brendza R.P., Bacskai B.J., Cirrito J.R., Simmons K.A., Skoch J.M., Klunk W.E., Mathis C.A., Bales K.R., Paul S.M., Hyman B.T., Holtzman D.M. Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J. Clin. Invest. 2005, 115:428-433.
10. Bruno M.A., Cuello A.C. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6735-6740.
11. Bruno M.A., Leon W.C., Fragoso G., Mushynski W.E., Almazan G., Cuello A.C. Amyloid beta-induced nerve growth factor dysmetabolism in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2009, 68:857-869.
12. Bulbarelli A., Lonati E., Cazzaniga E., Re F., Sesana S., Barisani D., Sancini G., Mutoh T., Masserini M. TrkA pathway activation induced by amyloid-beta (Abeta). Mol. Cell. Neurosci. 2009, 40:365-373.
13. Buttini M., Yu G.Q., Shockley K., Huang Y., Jones B., Masliah E., Mallory M., Yeo T., Longo F.M., Mucke L. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J. Neurosci. 2002, 22:10539-10548.
14. Caccamo A., Oddo S., Billings L.M., Green K.N., Martinez-Coria H., Fisher A., LaFerla F.M. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006, 49:671-682.
15. Carroll J.C., Rosario E.R., Chang L., Stanczyk F.Z., Oddo S., LaFerla F.M., Pike C.J. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J. Neurosci. 2007, 27:13357-13365.
16. Cataldo A.M., Peterhoff C.M., Troncoso J.C., Gomez-Isla T., Hyman B.T., Nixon R.A. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 2000, 157:277-286.
17. Chen L., Yamada K., Nabeshima T., Sokabe M. Alpha7 Nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats. Neuropharmacology 2006, 50:254-268.
18. Conner J.M., Varon S. Distribution of nerve growth factor-like immunoreactive neurons in the adult rat brain following colchicine treatment. J. Comp. Neurol. 1992, 326:347-362.
19. Cooper J.D., Salehi A., Delcroix J.D., Howe C.L., Belichenko P.V., Chua-Couzens J., Kilbridge J.F., Carlson E.J., Epstein C.J., Mobley W.C. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10439-10444.
20. Costantini C., Weindruch R., Della Valle G., Puglielli L. A TrkA-to-p75NTR molecular switch activates amyloid beta-peptide generation during aging. Biochem. J. 2005, 391:59-67.
21. Counts S.E., Nadeem M., Wuu J., Ginsberg S.D., Saragovi H.U., Mufson E.J. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Ann. Neurol. 2004, 56:520-531.
22. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983, 219:1184-1190.
23. Cuello A.C., Bruno M.A. The failure in NGF maturation and its increased degradation as the probable cause for the vulnerability of cholinergic neurons in Alzheimer's disease. Neurochem. Res. 2007, 32:1041-1045.
24. D'Amore J.D., Kajdasz S.T., McLellan M.E., Bacskai B.J., Stern E.A., Hyman B.T. In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories. J. Neuropathol. Exp. Neurol. 2003, 62:137-145.
25. Davies P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer's type. Brain Res. 1979, 171:319-327.
26. Davies P., Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, 2:1403.
27. DeKosky S.T., Harbaugh R.E., Schmitt F.A., Bakay R.A., Chui H.C., Knopman D.S., Reeder T.M., Shetter A.G., Senter H.J., Markesbery W.R. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group. Ann. Neurol. 1992, 32:625-632.
28. DeKosky S.T., Ikonomovic M.D., Styren S.D., Beckett L., Wisniewski S., Bennett D.A., Cochran E.J., Kordower J.H., Mufson E.J. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol. 2002, 51:145-155.
29. Fahnestock M., Michalski B., Xu B., Coughlin M.D. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol. Cell. Neurosci. 2001, 18:210-220.
30. Fahnestock M., Yu G., Michalski B., Mathew S., Colquhoun A., Ross G.M., Coughlin M.D. The nerve growth factor precursor proNGF exhibits neurotrophic activity but is less active than mature nerve growth factor. J. Neurochem. 2004, 89:581-592.
31. Fombonne J., Rabizadeh S., Banwait S., Mehlen P., Bredesen D.E. Selective vulnerability in Alzheimer's disease: amyloid precursor protein and p75(NTR) interaction. Ann. Neurol. 2009, 65:294-303.
32. Fonnum F. A rapid radiochemical method for the determination of choline acetyltransferase. J. Neurochem. 1975, 24:407-409.
33. Frade J.M., Barde Y.A. Nerve growth factor: two receptors, multiple functions. Bioessays 1998, 20:137-145.
34. Garzon D.J., Fahnestock M. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J. Neurosci. 2007, 27:2628-2635.
35. German D.C., Yazdani U., Speciale S.G., Pasbakhsh P., Games D., Liang C.L. Cholinergic neuropathology in a mouse model of Alzheimer's disease. J. Comp. Neurol. 2003, 462:371-381.
36. Geula C., Mesulam M.M. Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cereb. Cortex 1996, 6:165-177.
37. Gilmor M.L., Erickson J.D., Varoqui H., Hersh L.B., Bennett D.A., Cochran E.J., Mufson E.J., Levey A.I. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J. Comp. Neurol. 1999, 411:693-704.
38. Gundersen H.J., Bagger P., Bendtsen T.F., Evans S.M., Korbo L., Marcussen N., Moller A., Nielsen K., Nyengaard J.R., Pakkenberg B., et al. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 1988, 96:857-881.
39. Hartley D.M., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M., Teplow D.B., Selkoe D.J. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 1999, 19:8876-8884.
40. Hernandez D., Sugaya K., Qu T., McGowan E., Duff K., McKinney M. Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes. Neuroreport 2001, 12:1377-1384.
41. Hirata-Fukae C., Li H.F., Hoe H.S., Gray A.J., Minami S.S., Hamada K., Niikura T., Hua F., Tsukagoshi-Nagai H., Horikoshi-Sakuraba Y., Mughal M., Rebeck G.W., LaFerla F.M., Mattson M.P., Iwata N., Saido T.C., Klein W.L., Duff K.E., Aisen P.S., Matsuoka Y. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res. 2008, 24:92-103.
42. Holtzman D.M., Li Y., Chen K., Gage F.H., Epstein C.J., Mobley W.C. Nerve growth factor reverses neuronal atrophy in a Down syndrome model of age-related neurodegeneration. Neurology 1993, 43:2668-2673.
43. Hu L., Wong T.P., Cote S.L., Bell K.F., Cuello A.C. The impact of Abeta-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in Alzheimer's disease-like transgenic mice. Neuroscience 2003, 121:421-432.
44. Huang E.J., Reichardt L.F. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 2001, 24:677-736.
45. Ikonomovic M.D., Abrahamson E.E., Isanski B.A., Wuu J., Mufson E.J., DeKosky S.T. Superior frontal cortex cholinergic axon density in mild cognitive impairment and early Alzheimer's disease. Arch. Neurol. 2007, 64:1312-1317.
46. Jaffar S., Counts S.E., Ma S.Y., Dadko E., Gordon M.N., Morgan D., Mufson E.J. Neuropathology of mice carrying mutant APP (swe) and/or PS1 (M146L) transgenes: alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway. Exp. Neurol. 2001, 170:227-243.
47. Knowles J.K., Rajadas J., Nguyen T.V., Yang T., LeMieux M.C., Vander Griend L., Ishikawa C., Massa S.M., Wyss-Coray T., Longo F.M. The p75 neurotrophin receptor promotes amyloid-beta(1-42)-induced neuritic dystrophy in vitro and in vivo. J. Neurosci. 2009, 29:10627-10637.
48. Lad S.P., Neet K.E., Mufson E.J. Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Curr. Drug Targets CNS Neurol. Disord. 2003, 2:315-334.
49. Lee R., Kermani P., Teng K.K., Hempstead B.L. Regulation of cell survival by secreted proneurotrophins. Science 2001, 294:1945-1948.
50. Liu L., Ikonen S., Tapiola T., Tanila H., van Groen T. Fimbria-fornix lesion does not affect APP levels and amyloid deposition in the hippocampus of APP+PS1 double transgenic mice. Exp. Neurol. 2002, 177:565-574.
51. Lombardo J.A., Stern E.A., McLellan M.E., Kajdasz S.T., Hickey G.A., Bacskai B.J., Hyman B.T. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J. Neurosci. 2003, 23:10879-10883.
52. Luth H.J., Apelt J., Ihunwo A.O., Arendt T., Schliebs R. Degeneration of beta-amyloid-associated cholinergic structures in transgenic APP SW mice. Brain Res. 2003, 977:16-22.
53. Masliah E., Sisk A., Mallory M., Mucke L., Schenk D., Games D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J. Neurosci. 1996, 16:5795-5811.
54. Masoudi R., Ioannou M.S., Coughlin M.D., Pagadala P., Neet K.E., Clewes O., Allen S.J., Dawbarn D., Fahnestock M. Biological activity of nerve growth factor precursor is dependent upon relative levels of its receptors. J. Biol. Chem. 2009, 284:18424-18433.
55. Mastrangelo M.A., Bowers W.J. Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. BMC Neurosci. 2008, 9:81.
56. Mathews P.M., Guerra C.B., Jiang Y., Grbovic O.M., Kao B.H., Schmidt S.D., Dinakar R., Mercken M., Hille-Rehfeld A., Rohrer J., Mehta P., Cataldo A.M., Nixon R.A. Alzheimer's disease-related overexpression of the cation-dependent mannose 6-phosphate receptor increases Abeta secretion: role for altered lysosomal hydrolase distribution in beta-amyloidogenesis. J. Biol. Chem. 2002, 277:5299-5307.
57. Mesulam M.M., Mufson E.J., Levey A.I., Wainer B.H. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J. Comp. Neurol. 1983, 214:170-197.
58. Mufson E.J., Bothwell M., Kordower J.H. Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: a quantitative analysis across subregions of the basal forebrain. Exp. Neurol. 1989, 105:221-232.
59. Mufson E.J., Ma S.Y., Cochran E.J., Bennett D.A., Beckett L.A., Jaffar S., Saragovi H.U., Kordower J.H. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J. Comp. Neurol. 2000, 427:19-30.
60. Mufson E.J., Ma S.Y., Dills J., Cochran E.J., Leurgans S., Wuu J., Bennett D.A., Jaffar S., Gilmor M.L., Levey A.I., Kordower J.H. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J. Comp. Neurol. 2002, 443:136-153.
61. Mufson E.J., Counts S.E., Perez S.E., Ginsberg S.D. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev. Neurother. 2008, 8:1703-1718.
62. Nagele R.G., D'Andrea M.R., Anderson W.J., Wang H.Y. Intracellular accumulation of beta-amyloid (1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 2002, 110:199-211.
63. Nixon R.A. Autophagy, amyloidogenesis and Alzheimer disease. Cell Sci. 2007, 120:4081-4091.
64. Nykjaer A., Lee R., Teng K.K., Jansen P., Madsen P., Nielsen M.S., Jacobsen C., Kliemannel M., Schwarz E., Willnow T.E., Hempstead B.L., Petersen C.M. Sortilin is essential for proNGF-induced neuronal cell death. Nature 2004, 427:843-848.
65. Oddo S., Caccamo A., Kitazawa M., Tseng B.P., LaFerla F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 2003, 24:1063-1070.
66. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
67. Oh K.-J., Perez S.E., Lagalwar S., Vana L., Binder L., Mufson E.J. Staging of Alzheimer's pathology in triple transgenic mice: a light and electron microscopic analysis. Int. J. AD 2010, (epub).
68. Overk C.R., Kelley C.M., Mufson E.J. Brainstem Alzheimer's-like pathology in the triple transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 2009, 35:415-425.
69. Paxinos G., Franklin K.B.J. The mouse brain in stereotaxic coordinates 2001, Academic Press, San Diego. 2nd ed.
70. Perez S.E., Lazarov O., Koprich J.B., Chen E.Y., Rodriguez-Menendez V., Lipton J.W., Sisodia S.S., Mufson E.J. Nigrostriatal dysfunction in familial Alzheimer's disease-linked APPswe/PS1DeltaE9 transgenic mice. J. Neurosci. 2005, 25:10220-10229.
71. Perez S.E., Dar S., Ikonomovic M.D., DeKosky S.T., Mufson E.J. Cholinergic forebrain degeneration in the APPswe/PS1DeltaE9 transgenic mouse. Neurobiol. Dis. 2007, 28:3-15.
72. Perry E.K., Tomlinson B.E., Blessed G., Bergmann K., Gibson P.H., Perry R.H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J. 1978, 2:1457-1459.
73. Phinney A.L., Deller T., Stalder M., Calhoun M.E., Frotscher M., Sommer B., Staufenbiel M., Jucker M. Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in amyloid precursor protein transgenic mice. J. Neurosci. 1999, 19:8552-8559.
74. Pigino G., Morfini G., Pelsman A., Mattson M.P., Brady S.T., Busciglio J. Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J. Neurosci. 2003, 23:4499-4508.
75. Richter J.A., Perry E.K., Tomlinson B. Acetylcholine and choline levels in post-mortem human brain tissue: preliminary observations in Alzheimer's disease. Life Sci. 1980, 26:1683-1689.
76. Robertson R.T., Baratta J., Yu J., LaFerla F.M. Amyloid-beta expression in retrosplenial cortex of triple transgenic mice: relationship to cholinergic axonal afferents from medial septum. Neuroscience 2009, 164:1334-1346.
77. Rosario E.R., Carroll J.C., Oddo S., LaFerla F.M., Pike C.J. Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease. J. Neurosci. 2006, 26:13384-13389.
78. Salehi A., Delcroix J.D., Belichenko P.V., Zhan K., Wu C., Valletta J.S., Takimoto-Kimura R., Kleschevnikov A.M., Sambamurti K., Chung P.P., Xia W., Villar A., Campbell W.A., Kulnane L.S., Nixon R.A., Lamb B.T., Epstein C.J., Stokin G.B., Goldstein L.S., Mobley W.C. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 2006, 51:29-42.
79. Seo H., Isacson O. Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Exp. Neurol. 2005, 193:469-480.
80. Sobreviela T., Clary D.O., Reichardt L.F., Brandabur M.M., Kordower J.H., Mufson E.J. TrkA-immunoreactive profiles in the central nervous system: colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin. J. Comp. Neurol. 1994, 350:587-611.
81. Suzuki T., Araki Y., Yamamoto T., Nakaya T. Trafficking of Alzheimer's disease-related membrane proteins and its participation in disease pathogenesis. J. Biochem. 2006, 139:949-955.
82. Tuszynski M.H., Thal L., Pay M., Salmon D.P., U.H.S., Bakay R., Patel P., Blesch A., Vahlsing H.L., Ho G., Tong G., Potkin S.G., Fallon J., Hansen L., Mufson E.J., Kordower J.H., Gall C., Conner J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 2005, 11:551-555.
83. Walsh D.M., Selkoe D.J. A beta oligomers - a decade of discovery. J. Neurochem. 2007, 101:1172-1184.
84. Wang H.Y., Lee D.H., D'Andrea M.R., Peterson P.A., Shank R.P., Reitz A.B. Beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J. Biol. Chem. 2002, 275:5626-5632.
85. West M.J. New stereological methods for counting neurons. Neurobiol. Aging 1993, 14:275-285.
86. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., DeLong M.R. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 1981, 10:122-126.
87. Whitehouse P.J., Struble R.G., Hedreen J.C., Clark A.W., Price D.L. Alzheimer's disease and related dementias: selective involvement of specific neuronal systems. CRC Crit. Rev. Clin. Neurobiol. 1985, 1:319-339.
88. Wilcock G.K., Esiri M.M., Bowen D.M., Smith C.C. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J. Neurol. Sci. 1982, 57:407-417.
89. Wong T.P., Debeir T., Duff K., Cuello A.C. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J. Neurosci. 1999, 19:2706-2716.
90. Yaar M., Zhai S., Pilch P.F., Doyle S.M., Eisenhauer P.B., Fine R.E., Gilchrest B.A. Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. J. Clin. Invest. 1997, 100:2333-2340.
91. Yang D.S., Kumar A., Stavrides P., Peterson J., Peterhoff C.M., Pawlik M., Levy E., Cataldo A.M., Nixon R.A. Neuronal apoptosis and autophagy cross talk in aging PS/APP mice, a model of Alzheimer's disease. Am. J. Pathol. 2008, 173:665-681.